Compare Stanley Black & Decker, Inc. (SWK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs Viatris Inc — how do they compare? Stanley Black & Decker, Inc. trades at $87.62 (market cap $13.60B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.79%). Which is the better fit depends on your goals.
| SWK | VTRS | |
|---|---|---|
Market Cap | $13.60B | $19.79B |
52-Week High | $94.12 | $17.39 |
52-Week Low | $62.12 | $8.74 |
Enterprise Value | $19.77B | $32.00B |
Dividend Yield | 3.79% | 2.83% |
Sector | — | Health |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $88.19, down 2.2% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.80 surpassing the $0.59 estimate. Fundamentals reveal a P/E of 35.86 and net income margin of 2.44%, while cash flow trends indicate stable operations. Recent news highlights strength in aerospace and automotive segments but notes weak Tools & Outdoor demand.
SWK offers value with a P/S of 0.87 and dividend yield appeal, but high debt and margin pressures pose risks. The consensus price target is $83.00, with 43% of analysts rating it a buy. Earnings growth and debt reduction are key catalysts, though sector headwinds and economic sensitivity remain concerns for investors.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
